MedWatch
Pharma & biotech

Novo CEO is on the hunt for future growth: "The pressure is bigger than ever"

Lars Fruergaard Jørgensen and the rest of Novo Nordisk are starting to plan for the future, when the firm's crucial patents have expired. This is a big task that requires a lot of effort, the CEO says.
At the turn of the year, Lars Fruergaard Jørgensen will have been the CEO of Novo Nordisk for the past five years. He took over the role on Jan. 1, 2017, after the firm's former long-standing CEO Lars Rebien Sørensen. "The five years have just flown by. Time has gone extreme fast," says Fruergaard Jørgensen. | Photo: Stine Bidstrup/ERH
At the turn of the year, Lars Fruergaard Jørgensen will have been the CEO of Novo Nordisk for the past five years. He took over the role on Jan. 1, 2017, after the firm's former long-standing CEO Lars Rebien Sørensen. "The five years have just flown by. Time has gone extreme fast," says Fruergaard Jørgensen. | Photo: Stine Bidstrup/ERH
Finans
by BENJAMIN WERNER CHRISTENSEN, translated by catherine brett and daniel pedersen

The thought of executing another formidable decade with high growth and continued progress is a bit of a headache for the CEO of Novo Nordisk.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Related articles:

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading

Jobs

See all jobs